I-131-Apamistamab(I-131-Apamistamab) - 药物靶点：CD45_在研适应症：难治性急性髓细胞白血病，复发性急性髓细胞白血病，复发性弥漫性大B细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

抗体偶联核素、治疗用放射药物

别名

131 I-Apamistamab、131-I-labeled BC8 antibody、131-I-labeled anti-CD45 antibody

+ [13]

靶点

CD45

作用方式

抑制剂

作用机制

CD45抑制剂(白细胞共同抗原抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病免疫系统疾病

在研适应症

难治性急性髓细胞白血病复发性急性髓细胞白血病复发性弥漫性大B细胞淋巴瘤+ [1]

非在研适应症-

原研机构

Fred Hutchinson Cancer Research Center

在研机构

Actinium Pharmaceuticals, Inc.

The University of Texas Southwestern Medical Center

非在研机构-

权益机构

Immedica Pharma AB

Actinium Pharmaceuticals, Inc.

University of California, Davis

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

Sequence Code 616719846H

来源: *****

Sequence Code 616719847L

来源: *****

关联

3

项与 I-131-Apamistamab 相关的临床试验

NCT06768905

/ Recruiting临床1/2期IIT

IOMAB-ACT: A Phase Ib/II Multi-institutional Study of 131 I-Apamistamab Followed by CD19-Targeted CAR-T Cell Therapy for Patients With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).

开始日期2025-04-25

申办/合作机构

The University of Texas Southwestern Medical Center

[+1]

NCT04512716

/ Recruiting早期临床1期IIT

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

开始日期2021-02-02

申办/合作机构

Memorial Sloan Kettering Cancer Center

NCT02665065

/ Active, not recruiting临床3期

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).

开始日期2016-06-01

申办/合作机构

Actinium Pharmaceuticals, Inc.

100 项与 I-131-Apamistamab 相关的临床结果

登录后查看更多信息

100 项与 I-131-Apamistamab 相关的转化医学

登录后查看更多信息

100 项与 I-131-Apamistamab 相关的专利（医药）

登录后查看更多信息

8

项与 I-131-Apamistamab 相关的文献（医药）

2025-01-10·Journal of Clinical Oncology

Randomized Phase III SIERRA Trial of ¹³¹ I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

Article

作者: Foran, James ; Law, Arjun Datt ; Munshi, Pashna ; Sabloff, Mitchell ; Tomlinson, Benjamin ; Cook, Rachel ; MacDougall, James ; Silverman, Margarida ; Desai, Avinash ; Sandmaier, Brenda M. ; Stiff, Patrick ; Kebriaei, Partow ; Pagel, John M. ; Litzow, Mark R. ; Chen, George ; Schuster, Michael ; Giralt, Sergio ; McNamara, Kathleen ; Al-Kadhimi, Zaid ; Lazarus, Hillard M. ; Reddy, Vijay ; Abhyankar, Sunil ; Hari, Parameswaran ; Abboud, Camille ; Levy, Moshe Y. ; Seropian, Stuart ; Koshy, Nebu ; Choe, Hannah ; Nath, Rajneesh ; Haeuber, Elaina ; Pandit-Taskar, Neeta ; Spross, Jennifer ; Rowley, Scott D. ; Vusirikala, Madhuri ; Larkin, Karilyn ; Van Besien, Koen ; Jamieson, Katarzyna ; Nahar, Akash ; Orozco, Johnnie J. ; Gyurkocza, Boglarka

PURPOSE Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131 I-apamistamab with conventional care. METHODS SIERRA (ClinicalTrials.gov identifier: NCT02665065 ) was a phase III open-label trial. Patients age ≥55 years with active RR AML were randomly assigned 1:1 to either an 131 I-apamistamab–led regimen before alloHCT or conventional care followed by alloHCT if initial complete remission (CR)/CR with incomplete platelet recovery (CRp) occurred. Initial response was assessed 28-56 days after alloHCT in the 131 I-apamistamab group and 28-42 days after salvage chemotherapy initiation; patients without CR/CRp or with AML progression could cross over to receive 131 I-apamistamab followed by alloHCT. The primary end point was durable complete remission (dCR) lasting 180 days after initial CR/CRp. Secondary end points were overall survival (OS) and event-free survival (EFS), assessed hierarchically in the intention-to-treat (ITT) population. RESULTS The ITT population included 153 patients ( 131 I-apamistamab [n = 76]; conventional care [n = 77]). In total, 44/77 conventional care arm patients crossed over and 40/77 (52%) received 131 I-apamistamab and alloHCT, with six patients (13.6%) experiencing a dCR. In the ITT population, the dCR rate was significantly higher with 131 I-apamistamab (17.1% [95% CI, 9.4 to 27.5]) than conventional care (0% [95% CI, 0 to 4.7]; P < .0001). The OS hazard ratio (HR) was 0.99 (95% CI, 0.70 to 1.41; P = .96), and the EFS HR was 0.23 (95% CI, 0.15 to 0.34), with HR <1 favoring 131 I-apamistamab. Grade ≥3 treatment-related adverse events occurred in 59.7% and 59.2% of the 131 I-apamistamab and conventional care groups, respectively. CONCLUSION The 131 I-apamistamab–led regimen was associated with a higher dCR rate than conventional care in older patients with RR AML. 131 I-apamistamab was well tolerated and could address an unmet need in this population.

2009-06-04·Blood1区 · 医学

131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma

1区 · 医学

Article

作者: Wilbur, Shani ; Press, Oliver W. ; Fromm, Jonathan R. ; Gopal, Ajay K. ; Pagel, John M.

AbstractRadioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) are limited. We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL. CD45 was highly expressed on hT-NHL patient samples (median, 2.3 × 105 antigen-binding capacity units/cell) and hT-NHL cell lines (3.4 × 105 CD45 antigen-binding capacity units/cell). Biodistribution studies in hTNHL xenografts showed that 131I-labeled BC8 (anti-hCD45) delivered 154% (P = .01) and 237% (P = .002) more radioiodine to tumor sites over control antibodies at 24 hours and 48 hours, respectively. Importantly, tumor sites targeted with 131I-BC8 exhibited 2.5-fold (P = .05), 3.0-fold (P = .007), and 3.6-fold (P = .07) higher 131I retention over the nontarget organs of lungs, liver, and kidneys, respectively (24 hours). Because the clinical use of anti-hCD45 would target both T-NHL and other hematolymphoid tissues, we evaluated the ability of anti-mCD45 to target mT-NHL. mT-NHL grafts targeted with anti-mCD45 correspondingly retained 5.3 (P < .001), 5.4 (P < .001), and 8.7 (P < .001) times the radioactivity in tumor sites compared with nontarget organs of lung, liver, and kidney. 131I-labeled BC8 therapy yielded improved complete remission rates (75% vs 0%, P < .001) and progression-free survivals (median, 23 days vs 4.5 days, P < .001) compared with controls. These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients.

2006-10-01·Indian journal of experimental biology

Heat stress induced apoptosis in BC-8 cells derived from AK-5 tumor involves downregulation of Bcl-2 and generation of reactive oxygen species.

Article

作者: Varalakshmi, Ch ; Khar, Ashok ; Pardhasaradhi, B V V ; Rangaraj, Nandini ; Kumari, A Leela

BC-8, a rat histiocytoma undergoes apoptosis after heat shock, which is due to lack of an effective heat shock response. Heat shock induced generation of free radicals, which in turn are involved in the induction of apoptotic death in BC-8 cells. Treatment of BC-8 cells with N-acetylcysteine partially inhibited the heat induced apoptosis. Introduction of Bcl-2 gene in these cells did not protect them from apoptotic death, whereas transfection with hsp-70 gene did render these cells resistant to heat induced apoptosis transiently. Heat shock also downregulated the expression of Bcl-2 and p53 in these cells. These observations suggested that the heat shock induced apoptosis was mediated through reactive oxygen species and controlled upstream of Bcl-2 check point.

105

项与 I-131-Apamistamab 相关的新闻（医药）

2025-04-22

·创药网

【技术剖析】技术革新驱动核药产业系统性创新（一）

近年来，核药领域迎来爆发式增长。在精准医疗与诊疗一体化理念驱动下，核药创新技术加速升级，呈现出"核素迭代、靶标拓展、平台创新"等创新趋势。新型α核素药物、新功能靶向分子、智能开发平台等技术突破正重塑核药研发范式。本文概述了核药重磅交易和代表性RDC上市和在研药物，供研发人员参考。近年来，核药领域迎来爆发式增长。据统计，2024年核药市场规模达175亿美元，复合增长率13.48%，全球临床阶段核药管线超600项。在精准医疗与诊疗一体化理念驱动下，核药创新技术加速升级，呈现出"核素迭代、靶标拓展、平台创新"等创新趋势。新型α核素药物、新功能靶向分子、智能开发平台等技术突破正重塑核药研发范式。随着诺华Pluvicto在转移性去势抵抗性前列腺癌治疗中的成功，核药产业竞争焦点已从同位素选择转向系统性技术革新。一、α核素开启精准杀伤新时代靶向α治疗（Targeted Alpha Therapy，TAT）疗法是近年来核药领域的突破性方向，主要利用高能α粒子对肿瘤细胞进行精准杀伤。相比传统的β射线核素，α粒子具备更短的穿透深度和更高的线性能量转移（LET），能够在细胞层面实现高效破坏，同时降低对周围正常组织的损伤。其中，锕225（225Ac）凭借多阶段杀伤拓展难治瘤种，铅212（212Pb）以“短平快”的α治疗重塑临床范式，硼10（10B）则通过诊疗精准性开辟实体瘤新路径。创新性核素应用推动核药从“广谱杀伤”向“精准放疗2.0”升级。值得注意的是，同位素供应短缺是核药行业面临的最大挑战之一。在生产方面，现有创新技术包括原料替代，如212Pb用228Th替代铀矿，225Ac用核废料替代纯钍矿，10B开发新型前驱体；同时，使用模块化热室（212Pb）、在线辐照（225Ac）、超低温精馏（10B）等工艺革新技术；另有Telix公司构建"钍矿-分离-制剂"全链条，中核集团实现"反应堆-精馏-应用"闭环等产业协同创新流程，不断推动创新核素在核药开发中的精准诊疗应用（表1）。表1：创新α核素与传统核素对比核药的精准打击优势和技术迭代潜力持续吸引资本与产业资源（表2）。2024年2月，由诺贝尔化学奖得主Michael Welch教授创立的AlphaThera Bio宣布完成8500万美元A轮融资，致力于开发基于225Ac和镭223（223Ra）的TAT平台，并解决放射性核素稳定性和体内清除的挑战。自2023年以来，核药领军企业诺华分别与Bicycle Therapeutics、3B Pharmaceuticals、PeptiDream、Mariana Oncology等多家公司达成收购或药物开发合作，总金额近70亿美元。2024年7月，Novartis宣布与Radiomedix达成合作协议，开发TAT治疗方案，前期支付2000万美元，合作总金额超过10亿美元。2024年11月，诺华再与Ratio Therapeutics公司达成合作，共同开发针对生长抑素受体2（SSTR2）的放射性治疗药物，利用Ratio公司在放射配体治疗（RLT）发现和开发方面的专业知识及其两个专有研发平台——Trillium和Macropa，Trillium是一种药代动力学调控平台，能够针对任何特异性抗原靶标进行调控；Macropa是一种同位素225Ac螯合剂，这些平台均能够提升α粒子的肿瘤杀伤力。其中，国内药企东诚药业、远大医药等通过技术引进和合作加速国产替代。表2：近两年核药的重磅交易列举二、精准靶向及诊疗一体化1RDCRDC（Radionuclide Drug Conjugates）是一类创新的放射性药物，将精准靶向分子（单抗或多肽/小分子，Ligand）和强力杀伤因子（核素，Radioisotope）用连接臂（Linker）螯合剂（Chelator）偶联在一起而设计开发的药物形态；得益于其特殊的作用机制，RDC可实现高精度诊断及在治疗疾病的过程中具有不易耐药等优点，成为临床实操中唯一能够实现诊疗一体化的药物，也被认为是目前核药靶向治疗领域最具潜力的发展方向之一。当前，全球已获批RDC药物11个，其中9个为诊断用，2款来自诺华公司分别为针对神经内分泌瘤的Lutathrea与前列腺癌Pluvicto为治疗性用药（表3）。Pluvicto是首个靶向前列腺特异性膜抗原（PSMA）的治疗性RDC药物，通过β射线精准杀伤肿瘤细胞，2024年销售额13.92亿美元。Lutathera是全球首款治疗性RDC，针对SSTR2阳性肿瘤，Ⅲ期试验显示疾病进展风险降低79%，2024年销售额7.24亿美元。两款治疗性RDC的良好市场表现，让整个市场对核药赛道展现出强劲信心。表3：已获批RDC诊疗法当前管线中，RDC药物研发较活跃，临床前及早期临床候选药物较丰富（图1）。进入临床后期的管线中，目前已递交上市申请的RDC候选药共有8个，其中有2个治疗性RDC的上市申请进展较为艰难，131I-Omburtamab（靶向B7-H3）的上市申请经历了多次波折，目前尚未在全球主要市场获批；131I-Apamistamab（商品名Iomab-B）作为一种靶向CD45的RDC，在复发/难治性急性髓系白血病（R/R AML）治疗中展现了突破性潜力，但其上市申请因监管要求未完全获批，目前处于战略合作调整阶段。进入Ⅲ期临床的RDC药物进展较为积极的治疗性RDC有8个（表4）。以225Ac-PSMA-617、RYZ101和177Lu-Edotreotide为代表的全球首创药物具备较强的市场竞争力。图1：全球RDC研发管线布局表4：处于Ⅲ期临床的RDC药物2PRC根据靶向配体的不同，RDC可细分为抗体偶联核素药物（ARC）、小分子偶联核素药物（SMRC）和多肽偶联核素药物（PRC）。PRC利用多肽将放射性同位素靶向递送至癌细胞中，通过“靶向多肽+核素”的精准设计，结合技术创新（如环肽、诊疗一体化），在实体瘤治疗中展现出独特优势。与抗体相比，多肽在组织渗透、药代动力学性质等方面优势独特，同时多肽蛋白的特异性表达与偶联功能可以满足RDC的技术突破方向要求。此外，通过环化改造（如形成环肽）或引入非天然氨基酸，可增强多肽的抗酶解能力和靶标亲和力。美国FDA已经批准多款靶向多肽核药，如Lutathera用的多肽是Octreotide（奥曲肽），证明了基于多肽分子开发RDC的可行性。2024年5月，诺华与PeptiDream公司开展多肽发现合作，利用其独有的多肽发现平台系统（PDPS），根据诺华指定的靶标，发现和优化创新大环肽。同月，诺华以17.5亿美元收购Mariana Oncology公司，该公司聚焦开发靶向肽核药，其主导项目MC-339是一种针对小细胞肺癌的在研的新型PRC，其携带的放射性同位素为锕系元素。本文其它内容请见创药网https://www.iddds.cn

并购临床研究

2025-04-14

·PRNewswire

ATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the Class

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B According to the complaint, during the class period, defendants misled investors to believe there was a very high likelihood that the FDA would review and approve the Company's Biologics License Application ("BLA") for Iomab-B. The complaint alleges that defendants (i) repeatedly touted the Sierra Trial's positive DCR data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming the FDA had blessed the design of the trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the BLA. On August 5, 2024, Actinium announced "the FDA has now determined that the analyses from the Sierra trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study." On this new, the price of Actinium's common stock fell $3.69, or approximately to 60%, to close at $2.48 on August 5, 2024. What Now: You may be eligible to participate in the class action against Actinium Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 26, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Actinium Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权

2025-03-28

·PRNewswire

Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO, March 28, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B According to the complaint, during the class period, defendants misled investors to believe there was a very high likelihood that the FDA would review and approve the Company's Biologics License Application ("BLA") for Iomab-B. The complaint alleges that defendants (i) repeatedly touted the Sierra Trial's positive DCR data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming the FDA had blessed the design of the trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the BLA. On August 5, 2024, Actinium announced "the FDA has now determined that the analyses from the Sierra trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study." On this new, the price of Actinium's common stock fell $3.69, or approximately to 60%, to close at $2.48 on August 5, 2024. What Now: You may be eligible to participate in the class action against Actinium Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 26, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Actinium Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权

100 项与 I-131-Apamistamab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性急性髓细胞白血病	临床3期	加拿大	Actinium Pharmaceuticals, Inc.	2016-06-01
难治性急性髓细胞白血病	临床3期	美国	Actinium Pharmaceuticals, Inc.	2016-06-01
复发性急性髓细胞白血病	临床3期	加拿大	Actinium Pharmaceuticals, Inc.	2016-06-01
复发性急性髓细胞白血病	临床3期	美国	Actinium Pharmaceuticals, Inc.	2016-06-01
复发性弥漫性大B细胞淋巴瘤	临床2期	美国	The University of Texas Southwestern Medical Center	2025-04-25
复发性弥漫性大B细胞淋巴瘤	临床2期	美国	Actinium Pharmaceuticals, Inc.	2025-04-25
难治性弥漫性大 B 细胞淋巴瘤	临床2期	美国	The University of Texas Southwestern Medical Center	2025-04-25
难治性弥漫性大 B 细胞淋巴瘤	临床2期	美国	Actinium Pharmaceuticals, Inc.	2025-04-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	-	-	Iomab-B	蓋鹹選齋構遞餘範願淵(繭蓋糧膚襯艱鏇鹹艱獵) = 簾簾襯鏇糧簾襯簾衊窪網壓築淵鏇網壓壓築襯 (鑰壓醖餘構窪憲齋膚窪 )	-	2024-06-09
NCT02665065 (SIERRA, EHA2024) 人工标引	临床3期	急性髓性白血病 CD45	153	Iomab-B with fludarabine and total body irradiation (2 Gy) followed by HCT	繭築糧積齋鹽窪蓋醖築(壓願製選蓋廠簾簾鹽壓) = 糧簾鬱顧範鏇壓網襯夢鏇繭簾簾製構鹽蓋遞膚 (壓餘窪壓選積夢淵淵願 ) 更多	积极	2024-05-14
				131I-APAMISTAMAB-LED (Physician’s choice of conventional care (CC))	繭築糧積齋鹽窪蓋醖築(壓願製選蓋廠簾簾鹽壓) = 夢繭遞蓋壓糧鹽夢積鑰鏇繭簾簾製構鹽蓋遞膚 (壓餘窪壓選積夢淵淵願 ) 更多
NCT02665065 (SIERRA, EHA2024) 人工标引	临床3期	急性髓性白血病	153	Iomab-B with fludarabine and total body irradiation	(糧構鏇願製構築鬱鑰壓) = 網艱獵製衊構鹽蓋顧襯範齋顧選構鑰願製艱淵 (鑰壓膚築構繭選鹹衊願 ) 更多	积极	2024-05-14
				131I-APAMISTAMAB-LED (Conventional Care)	(糧構鏇願製構築鬱鑰壓) = 範壓鹹壓艱憲願壓淵淵範齋顧選構鑰願製艱淵 (鑰壓膚築構繭選鹹衊願 ) 更多
NCT02665065 (SIERRA, EBMT2024) 人工标引	临床3期	急性髓性白血病	153	Iomab-B	(觸遞觸築網夢鹽齋餘獵) = 簾壓鬱夢蓋選齋鬱鹽選願鹹艱餘繭蓋繭蓋蓋鹹 (構繭構鏇築艱鹹醖遞衊 )	积极	2024-04-17
NCT02665065 (SIERRA, Biospace) 人工标引	临床3期	急性髓性白血病	54	Iomab-B	(鑰壓壓鏇觸願夢顧艱衊) = 壓窪構鏇齋艱鑰齋鑰範觸網鑰遞鹽網壓繭網淵 (網積窪齋憲製艱壓廠糧 ) 更多	积极	2024-02-26
				Crossover	(鑰壓壓鏇觸願夢顧艱衊) = 製鏇顧衊構簾顧顧網網觸網鑰遞鹽網壓繭網淵 (網積窪齋憲製艱壓廠糧 ) 更多
NCT02665065 (SIERRA, Tandem Meetings ASTCT and CIBMTR2024) 人工标引	临床3期	急性髓性白血病	153	Iomab-B with fludarabine and total body irradiation	(積獵築憲選壓繭憲醖願) = 醖構襯顧齋積衊網願簾壓廠壓廠鑰鹽膚觸繭鬱 (繭獵願衊鬱鬱衊鹹糧顧 ) 更多	积极	2024-02-01
				Apamistamab (Conventional Care)	(積獵築憲選壓繭憲醖願) = 觸顧簾構觸壓醖鑰構鹹壓廠壓廠鑰鹽膚觸繭鬱 (繭獵願衊鬱鬱衊鹹糧顧 ) 更多
NCT02665065 (SIERRA, Biospace) 人工标引	临床3期	急性髓性白血病	153	Iomab-B (Crossover + TP53 Mutation)	(選鹹願蓋鏇願夢遞壓廠) = 遞願鏇鏇窪鹽範醖窪範鏇廠醖製壓遞艱膚製構 (製衊衊鬱願醖鏇築鹽範 ) 更多	积极	2023-12-11
				Control Arm (TP53 Mutation)	(選鹹願蓋鏇願夢遞壓廠) = 鬱蓋壓製廠鬱鹹窪齋壓鏇廠醖製壓遞艱膚製構 (製衊衊鬱願醖鏇築鹽範 ) 更多
NCT02665065 (SIERRA, EBMT2023) 人工标引	临床3期	急性髓性白血病二线	153	Iomab-B	蓋築衊鹽網膚廠構鏇積(齋鹽壓餘網壓構構製顧) = 範壓壓鏇衊鬱憲簾鑰膚糧鑰醖膚憲願選鏇獵積 (齋鹹夢製網糧鏇窪觸簾 ) 更多	积极	2023-04-26
				Conventional Care	蓋築衊鹽網膚廠構鏇積(齋鹽壓餘網壓構構製顧) = 鹽遞壓構獵艱鹽鑰獵齋糧鑰醖膚憲願選鏇獵積 (齋鹹夢製網糧鏇窪觸簾 ) 更多
NCT02665065 (SIERRA, EBMT2023)	临床3期	急性髓性白血病 CD45	153	Iomab-B based conditioning followed by HCT	(淵夢夢構夢夢範構餘觸) = 廠廠襯顧夢夢齋簾選鹹選構窪醖網艱餘壓衊網 (憲餘糧齋窪築夢鏇鏇鏇, 12.29 ~ 34.73) 更多	积极	2023-04-23
				Iomab-B (Physician's choice of conventional care)	(壓廠夢構鏇糧積鏇繭鹽) = 繭觸淵艱獵鏇餘鏇糧繭糧構壓壓選廠遞觸鹹鏇 (壓醖積齋壓餘壓鏇糧窪 ) 更多
NCT02665065 (SIERRA, Corporate Publications) 人工标引	临床3期	急性髓性白血病	153	Iomab-B	(蓋醖簾壓繭淵製願壓鏇): P-Value = <0.0001	积极	2022-10-31
				conventional care